Allogene Therapeutics named Zachary Roberts as the next president and CEO, with plans for him to succeed David Chang on July 1. The shift comes after Chang co-founded the company and led it for about eight years, while Roberts currently serves as EVP of R&D and CMO at Allogene. The transition includes Roberts joining the board as part of the succession plan. The company framed the appointment as a continuation of its cell-therapy strategy, with Roberts positioned to steer development and manufacturing execution. Leadership changes can accelerate decision-making across clinical and operational domains in off-the-shelf cell therapies, where timing and supply chain performance directly affect trial enrollment and scale. The move is also likely to influence how investors interpret near-term development milestones. Industry observers will follow whether Roberts’ R&D and CMO background changes priorities around process development, clinical strategy sequencing, and internal governance.